NFE2L2 and hematologic disorder: Hence, it may be necessary for the patients with high-risk hematologic malignancies to intensively monitor the dose-escalated BU, combined with NRF2 -617CA/AA genotyping, in order to avoid the possible drug toxicities induced by high exposure.